Refining patient selection through predictive biomarkers and exploring combination therapies could help maximize the efficacy of IGF-1R-targeted treatment and provide potential therapeutic options for patients with refractory or recurrent ES as well as other tumors. Here, IGF1R is linked to Ewing sarcoma.